<DOC>
	<DOCNO>NCT01140906</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability safety two fixed dos vortioxetine treatment major depressive disorder .</brief_summary>
	<brief_title>Randomised Placebo-controlled Duloxetine-referenced Study Efficacy Safety 15 20 mg Vortioxetine ( Lu AA21004 ) Acute Treatment Major Depressive Disorder Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>The patient recurrent MDD primary diagnosis accord DSMIVTRâ„¢ criterion ( classification code 296.3x ) The patient MADRS total score &gt; =26 The patient CGIS score &gt; =4 The patient current episode MDE &gt; 3 month Any current anxiety psychiatric disorder define DSMIV TR Current diagnosis history manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIV TR Current diagnosis history alcohol substance abuse dependence ( exclude nicotine caffeine ) define DSMIV TR Use psychoactive medication 2 week prior screen study The patient significant risk suicide score &gt; =5 Item 10 ( suicidal thought ) MADRS , attempt suicide within 6 month prior Screening Visit Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Active reference</keyword>
	<keyword>Multicenter study</keyword>
	<keyword>Randomised study</keyword>
	<keyword>Acute treatment</keyword>
</DOC>